Smith & Nephew (SN.)

Sector:

Health Care

Index:

FTSE 100

1,078.00p
   
  • Change Today:
    -8.00p
  • 52 Week High: 1,425.00
  • 52 Week Low: 1,018.50
  • Currency: UK Pounds
  • Shares Issued: 872.51m
  • Volume: 498,489
  • Market Cap: £9,406m
  • RiskGrade: 173

Smith+Nephew Q1 revenues beat forecasts as elective surgeries resume

By Frank Prenesti

Date: Thursday 28 Apr 2022

LONDON (ShareCast) - (Sharecast News) - Medical products maker Smith+Nephew beat first quarter revenue forecasts as elective surgery volumes from the impact of the Omicron Covid variant at the start of the year.
The company on Thursday said revenue for the three months to April 2 rose 5.9% to $1.31bn on an underlying basis, above analysts' forecasts of a 2.8% rise to $1.27bn.

"Our Q1 performance puts us on track to deliver our guidance for this year," said newly-appointed chief executive Deepak Nath.

Smith+Nephew makes orthopaedic implants and prosthetics, along with wound dressings and other surgical technologies, which recorded strong performance in the quarter.

The company said revenue in its established markets rose 4.1% on an underlying basis as elective surgery volumes recovered from Omicron impact at the start of the quarter.

Emerging markets revenue wasup 14.3% underlying, with double-digit growth across India, the Middle East and Africa, and Latin America.

The company has been improving its internal networks and moving logistics to a third-party provider to address supply snags, while targeting 2022 underlying revenue growth of 4%-5%.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Smith and Nephew Market Data

Currency UK Pounds
Share Price 1,078.00p
Change Today -8.00p
% Change -0.74 %
52 Week High 1,425.00
52 Week Low 1,018.50
Volume 498,489
Shares Issued 872.51m
Market Cap £9,406m
RiskGrade 173

Smith and Nephew Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
74.17% below the market average74.17% below the market average74.17% below the market average74.17% below the market average74.17% below the market average
52.63% above the sector average52.63% above the sector average52.63% above the sector average52.63% above the sector average52.63% above the sector average
Price Trend
42.3% below the market average42.3% below the market average42.3% below the market average42.3% below the market average42.3% below the market average
10.00% above the sector average10.00% above the sector average10.00% above the sector average10.00% above the sector average10.00% above the sector average
Income
22.58% below the market average22.58% below the market average22.58% below the market average22.58% below the market average22.58% below the market average
80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average
Growth
10.44% below the market average10.44% below the market average10.44% below the market average10.44% below the market average10.44% below the market average
37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average

What The Brokers Say

Strong Buy 5
Buy 1
Neutral 6
Sell 0
Strong Sell 1
Total 13
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Smith and Nephew Dividends

  Latest Previous
  Interim Final
Ex-Div 29-Sep-22 31-Mar-22
Paid 26-Oct-22 11-May-22
Amount 14.40¢ 23.10¢

Trades for 09-Aug-2022

Time Volume / Share Price
12:32 94 @ 1,078.10p
12:31 175 @ 1,078.10p
12:30 697 @ 1,078.00p
12:30 372 @ 1,078.00p
12:30 709 @ 1,078.00p

Smith and Nephew Key Personnel

Chair Roberto Quarta
CEO Deepak Nath

Top of Page